Eloxx Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$2.47next fiscal year
Monitoring Framework
Key Performance Indicators
Exaluren Phase 2b EXACT Trial Initiation QuarterlyTarget: Initiation of Phase 2b clinical trial in Nonsense Mutation Alport Syndrome (NMAS) patients
Exaluren Phase 2b EXACT Trial Topline Data AnnuallyTarget: Placebo-controlled topline data from the initial 16-week part of the study
Exaluren Phase 2 Trial in nmADPKD Initiation AnnuallyTarget: Initiation of Phase 2 clinical trial in nonsense mutation Autosomal Dominant Polycystic Kidney Disease (nmADPKD)
Watch Items
- Cash Runway and Capital SufficiencyTrigger: Cash balance falling below $15.0 millionAction: Evaluate additional equity offerings, debt financing, or strategic out-licensing opportunities to sustain clinical operations.
- ZKN-013 Clinical Progress by AlmirallTrigger: Initiation of Phase 2 trials or achievement of development milestonesAction: Monitor partner progress to trigger potential milestone payments of up to $470 million under the exclusive licensing agreement.
Research as of 24 Jul 2026